Recently, a new tyrosine kinase inhibitor, axitinib, was approved for the treatment of advanced renal cell carcinoma for when one prior systemic therapy fails.
The approval was based on an international, randomized, open-label trial(AXIS trial) of patients with metastatic renal cell carcinoma who failed in one prior systemic regimen. The present manuscript summarizes this new drug and the AXIS trial.
Written by:
Ozono S, Takayama T. Are you the author?
Dept. of Urology, Hamamatsu University School of Medicine, Japan.
Reference: Gan To Kagaku Ryoho. 2013 Jan;40(1):26-9.
PubMed Abstract
PMID: 23306916
Article in Japanese.
UroToday.com Renal Cancer Section
